NeuBase Therapeutics plans dissolution as finances fall apart
The once-promising Pittsburgh biotech firm that developed precision genetic medicines set a board vote for May 13.
Source: technical.ly
Stay updated with breaking news from Stealth Editor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The once-promising Pittsburgh biotech firm that developed precision genetic medicines set a board vote for May 13.
New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide Symposium First non-human primate (NHP) study to successfully redose a gene editor without an immune r...